Track topics on Twitter Track topics that are important to you
Progression-free survival was longer with sunitinib in patients with papillary and unclassified histologies, but longer with everolimus in those with chromophobe histology.
A phase II trial found that cabozantinib offers significantly better progression-free survival over sunitinib in patients with untreated advanced RCC.
US-based biopharmaceutical company Exelixis has demonstrated improvement in progression-free survival (PFS) with cabozantinib, compared to sunitinib in patients with advanced intermediate or poor risk...
Adjuvant treatment with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase 3 study. Furthermore, substantial treat...
Sunitinib is an oral tyrosine kinase inhibitor used for cancer treatment. Patients treated with sunitinib are at higher bleeding risk. As tyrosine kinases are essential for platelet signalling, the ef...
Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mec...
To assess the efficacy and tolerability of sunitinib rechallenge in the third-line or later setting in patients with metastatic renal cell carcinoma (mRCC).
Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and a...
Tyrosine kinase inhibitor sunitinib therapy is effective in treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.
Bone metastasis from cancer of unknown primary (BMCUP) brings poor survival prognosis and its management remains controversial. Sunitinib (SUTENT) proved effective in many sorts of solid tumors but ha...